Calidi Biotherapeutics (CLDI) Current Assets (2021 - 2026)

Calidi Biotherapeutics has reported Current Assets for 6 years, with the latest figure at $5.4 million in Q2 2026.

• On a quarterly basis, Current Assets fell 10.27% year-over-year to $5.4 million in Q2 2026; TTM through Jun 2026 was $5.4 million, a 10.27% decrease from a year earlier, with the FY2025 full-year figure at $6.3 million, down 38.83% from the prior year.
• Current Assets was $5.4 million for Q2 2026 at Calidi Biotherapeutics, down from $6.3 million in the prior quarter.
• The five-year high for Current Assets was $11.7 million in Q3 2023, with the low at $268864.0 in Q1 2023.
• Average Current Assets over 5 years is $4.5 million, with a median of $2.2 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2024: Current Assets soared 2339.4% in 2023, then plunged 81.0% in 2024.
• Over 5 years, Current Assets stood at $786000.0 in 2022, then surged by 447.46% to $4.3 million in 2023, then soared by 137.67% to $10.2 million in 2024, then slumped by 38.83% to $6.3 million in 2025, then retreated by 13.24% to $5.4 million in 2026.
• The last three Current Assets figures came in at $5.4 million (Q2 2026), $6.3 million (Q4 2025), and $11.0 million (Q3 2025), per Business Quant data.